Chronic Kidney Disease (CKD)
A progressive, usually symptomless loss of kidney function affecting up to one in nine adults worldwide — and a condition in which even a small drop in glomerular filtration is linked, in large cohort studies, to a significantly higher risk of cardiovascular death.
Number of studies
2
Safety
Requires caution
Time to effects
Slowing the rate of eGFR decline with ACE inhibitors/ARBs or SGLT2 inhibitors can become measurable in clinical observation after a few months to a year, though the effect is usually assessed over a much longer, multi-year horizon, since CKD is a slowly progressive disease.
Who it's for
Table of contents
TL;DR
A progressive, usually symptomless loss of kidney function affecting up to one in nine adults worldwide — and a condition in which even a small drop in glomerular filtration is linked, in large cohort studies, to a significantly higher risk of cardiovascular death.
- →Early detection of reduced eGFR or albuminuria allows treatment that slows disease progression before irreversible loss of kidney function occurs
- →Controlling blood pressure and blood glucose in people with early CKD significantly reduces the pace of further kidney function decline
- →Identifying CKD allows appropriate dose adjustment for kidney-excreted drugs and avoidance of additional nephrotoxic factors
| Condition type | A sustained (>3 months) reduction in glomerular filtration and/or presence of kidney damage markers |
|---|---|
| Level of evidence | Strong — well-characterized epidemiology, KDIGO classification, and options for slowing progression |
| Target group | People with diabetes, hypertension, obesity, or over age 60 |
| Key risk factors | Diabetes, hypertension, obesity, cardiovascular disease, family history of kidney disease |
| Diagnosis | eGFR from creatinine (CKD-EPI formula), albuminuria / albumin-to-creatinine ratio, electrolytes |
| Status | A chronic, usually slowly progressive disease requiring regular nephrology monitoring |
Understand
Overview
Chronic kidney disease (CKD) is a sustained reduction in glomerular filtration rate (eGFR below 60 mL/min/1.73m²), persisting for longer than three months, and/or the presence of other markers of kidney damage, chiefly albuminuria, as defined by KDIGO (Kidney Disease: Improving Global Outcomes). Unlike acute kidney injury, which can be reversible, CKD is, in the vast majority of cases, a progressive disease — though the pace of that progression can be significantly slowed with appropriate treatment and risk-factor control.
The global prevalence of CKD is surprisingly high — a systematic review and meta-analysis by Hill and colleagues from 2016, drawing on data from many countries, estimated it at 11–13% of the adult population, with the vast majority of cases falling into moderate, stage 3 disease (eGFR 30–59 mL/min/1.73m²). The two most common causes of CKD worldwide remain diabetes and chronic hypertension, which damage the glomerular blood vessels through distinct but partially overlapping mechanisms. Rarer causes include chronic glomerulonephritis, polycystic kidney disease, chronic urinary tract obstruction, and prolonged use of nephrotoxic drugs.
One of the most practically important features of CKD is that for most of its course, the disease produces no noticeable symptoms. Fatigue, swelling, changes in urination, or hypertension usually appear only at advanced stages, once little functioning kidney tissue remains — which is why diagnosis in practice rests almost entirely on routine blood tests (creatinine converted to eGFR) and urine tests (albuminuria), rather than on how a patient feels. A large-scale meta-analysis by the CKD Prognosis Consortium from 2010, drawing on data from over a million people in the general population, showed that both reduced eGFR and elevated albuminuria are independently associated with an increased risk of death from any cause and cardiovascular death — a finding with far-reaching clinical implications, since it shows that even small deviations in these parameters shouldn't be dismissed.
Diagnosis and staging of CKD rely on the KDIGO classification, which combines the eGFR value (stages G1 through G5) with an albuminuria category (A1–A3) — the lower the eGFR and the higher the albuminuria, the greater the risk of progression to end-stage kidney failure and cardiovascular complications. The eGFR calculation itself, based on creatinine using the CKD-EPI formula, its limitations, and the interpretation of a single result are described in detail in our creatinine and eGFR entry — here we focus on the disease itself as a condition, its causes, course, and treatment.
It's worth understanding that a single abnormal eGFR result doesn't automatically mean a CKD diagnosis — by definition, the abnormality must be confirmed to persist for at least three months, to distinguish chronic kidney disease from a transient, acute decline in kidney function related to, for example, dehydration or an acute infection. This distinction matters practically, since acute kidney injury often resolves once the cause is removed, while CKD calls for a long-term approach.
Who might genuinely benefit from this knowledge? Primarily people with diabetes or hypertension — the two most common causes of CKD — as well as those who are obese, have a history of cardiovascular disease, a family history of kidney disease, or are simply over 60, in whom the natural, age-related decline in glomerular filtration compounds other risk factors. Regular screening in these groups allows CKD to be detected at a stage where intervention has the greatest potential to slow progression.
Chronic kidney disease remains a serious but largely manageable condition — with early detection, blood pressure and glycemic control, and avoidance of additional nephrotoxic factors, a substantial share of patients never reach end-stage kidney failure requiring dialysis. The key is regular monitoring, rather than waiting for symptoms, which in this disease usually appear too late to fully reverse the damage already done.
Mechanism of action
CKD usually begins with primary damage to nephrons — the kidney's basic functional units — most often from chronically elevated blood glucose (damaging glomerular blood vessels in diabetes) or chronically elevated blood pressure (overloading and damaging those same vessels through a different, hemodynamic mechanism). Regardless of the initial cause, the end result is a permanent loss of some functioning nephrons.
The remaining, still-functional nephrons respond to this loss with compensatory hyperfiltration — each increases its individual workload to keep total kidney filtration as close to normal as possible. This adaptation can mask progressive kidney damage for a time, since eGFR may remain relatively stable despite the loss of a substantial share of kidney tissue.
The problem is that hyperfiltration itself, though compensatory, is harmful over the longer term — increased pressure within the glomeruli accelerates their own damage and scarring (glomerulosclerosis), creating a self-perpetuating vicious cycle: nephron loss overloads the remaining nephrons, which accelerates their damage, leading to further nephron loss. This vicious cycle explains why CKD, once initiated, tends to progress even after the original cause is removed, though the pace of this process can be significantly slowed with appropriate drug treatment.
The progressive loss of functioning kidney tissue is reflected in a gradually declining eGFR, on the basis of which successive stages of disease severity are assigned according to the KDIGO classification (from G1, with preserved or mildly reduced filtration, to G5, corresponding to end-stage kidney failure). Alongside worsening filtration failure, the kidneys' endocrine functions also become disrupted — declining erythropoietin production (leading to anemia) and disturbed vitamin D metabolism and calcium-phosphate balance (leading to secondary bone disorders) — showing that CKD is a disease affecting the body far more broadly than through filtration alone.
Primary nephron damage
Most often from chronic hyperglycemia or hypertension, damaging the glomerular blood vessels.
Compensatory hyperfiltration
Remaining, healthy nephrons increase their workload to compensate for the loss of kidney tissue and maintain total filtration.
The glomerulosclerosis vicious cycle
Hemodynamic overload of remaining nephrons accelerates their own damage and scarring, driving further loss of functioning tissue.
Progressive eGFR decline and stage classification
Declining eGFR reflects lost functioning kidney tissue and forms the basis for KDIGO's CKD stage classification (G1–G5).
Evidence: strong — based on 2 studies in this database.
Benefits
Common myths
MythChronic kidney disease always causes noticeable symptoms.
FactFor most of its course, CKD is symptomless — symptoms usually appear only at advanced stages, which is why diagnosis relies on routine blood and urine tests rather than how you feel.
MythIf creatinine is normal, kidney function must be fine.
FactAn isolated creatinine value can be misleading, especially with low muscle mass — only converting it to eGFR and accounting for albuminuria gives a reliable picture of kidney function, as our creatinine and eGFR entry explains in more depth.
MythChronic kidney disease always leads to dialysis.
FactWith early detection and appropriate treatment, a substantial share of patients, especially at lower stages, never reach end-stage kidney failure requiring dialysis.
MythA high-protein diet is always healthy, regardless of kidney status.
FactWith advanced CKD, excessive protein intake can accelerate disease progression — recommended protein intake should be individually adjusted to disease stage, ideally with a nephrologist or dietitian.
Forms & variants
Chronic Kidney Disease (CKD) comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Stage G1–G2 (eGFR ≥60 mL/min/1.73m² with damage markers)
Normal or mildly reduced filtration, but with evidence of kidney damage, e.g., albuminuria — the disease is already active despite an apparently normal eGFR.
Best for: Risk-factor control and regular monitoring
Stage G3 (eGFR 30–59 mL/min/1.73m²)
Moderately reduced filtration, the most commonly diagnosed CKD stage in the general population.
Best for: Intensifying progression-slowing treatment and avoiding nephrotoxic drugs
Stage G4–G5 (eGFR <30 mL/min/1.73m²)
Advanced or end-stage kidney failure, with growing risk of metabolic complications.
Best for: Preparing for kidney replacement therapy under nephrology care
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
Acute kidney injury appears suddenly, often during infection, dehydration, or exposure to nephrotoxic drugs, and can be reversible once the cause is removed, while CKD is a sustained reduction in kidney function lasting more than three months, in most cases progressive.
In most cases, the damage already done isn't fully reversible, but the pace of further progression can be significantly slowed through blood pressure and glucose control and avoiding additional nephrotoxic factors — very early functional changes sometimes partly resolve once the cause is removed.
Frequency depends on disease stage — early stages usually need checks once or twice a year, while more advanced stages may call for monitoring every few months as advised by a doctor.
No — dietary recommendations depend on disease stage and should be individualized, ideally with a nephrologist or dietitian, rather than applied routinely right after diagnosis.
Key tests include urine albuminuria or the albumin-to-creatinine ratio, plus electrolyte monitoring, blood pressure, and, when indicated, kidney ultrasound.
What actually helps
ACE inhibitors or angiotensin receptor blockers
Strong evidenceReduce pressure within the glomeruli and slow disease progression, especially with coexisting albuminuria.
Strict glycemic control in people with diabetes
Strong evidenceReduces the rate of glomerular blood vessel damage, the most common cause of CKD worldwide.
SGLT2 inhibitors
Strong evidenceA newer drug class that in large clinical trials has shown reduced risk of CKD progression regardless of diabetes status.
Dietary modification and avoiding nephrotoxic drugs
Moderate evidenceLimiting sodium and adjusting protein intake to disease stage supports drug therapy but doesn't replace it once CKD is diagnosed.
What to combine with
Good combinations
Creatinine and eGFR (Estimated Glomerular Filtration Rate) — eGFR calculated from creatinine is the fundamental tool for diagnosing and staging CKD — the calculation mechanics and interpretation of a single result are covered in that entry.
Hypertension — Hypertension is both one of the main causes of CKD and one of its common consequences — blood pressure control remains a key element of slowing disease progression.
Safety
Side effects & contraindications
Possible side effects
Progressive CKD leads to end-stage kidney failure requiring dialysis or transplantation
Electrolyte disturbances, including hyperkalemia, and metabolic acidosis
Anemia resulting from reduced erythropoietin production by damaged kidneys
Bone disease and mineral disorders, including secondary hyperparathyroidism (so-called CKD-MBD)
Significantly elevated risk of cardiovascular complications, which remain the leading cause of death in CKD patients, more often than kidney failure itself
Contraindications
No significant contraindications at typical doses.
Interactions
Uncontrolled hypertension and diabetes remain the two most common causes and accelerating factors of CKD progression
Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) can further damage the kidneys, especially with already reduced function
Dehydration and episodes of acute kidney injury, for example during infection or contrast-enhanced imaging, can accelerate permanent eGFR decline
A high-sodium diet and very high protein intake in people with advanced CKD can increase the burden on the kidneys
Smoking is linked in observational studies to a faster rate of glomerular filtration decline
Certain nephrotoxic drugs, including aminoglycosides, iodinated contrast media, or long-term proton pump inhibitor use, require particular caution
Is it worth taking?
Who it's for
- People with diabetes or hypertension — the two most common causes of CKD worldwide
- People who are obese, have cardiovascular disease, or a family history of kidney disease
- People over 60, in whom the natural, age-related decline in glomerular filtration compounds other risk factors
Not for
- No significant contraindications at typical doses.
Evidence
Worth knowing
The global prevalence of chronic kidney disease is estimated at around 11–13% of the adult population (Hill et al. 2016).
Diabetes and hypertension together account for the majority of CKD cases worldwide.
Even a small reduction in eGFR or the presence of albuminuria is independently associated with significantly elevated cardiovascular death risk (Matsushita et al. 2010).
Most diagnosed CKD cases fall into stage 3, often detected incidentally on routine blood tests.
Studies
Both reduced eGFR and elevated albuminuria are independently and additively associated with increased risk of death from any cause and cardiovascular death in the general population.
Matsushita K et al. (Chronic Kidney Disease Prognosis Consortium), The Lancet, 2010
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
Strong evidenceMatsushita K, van der Velde M, Astor BC, et al. (Chronic Kidney Disease Prognosis Consortium) · The Lancet · 2010
A collaborative meta-analysis of individual participant data from 21 general-population cohorts (over one million people) found that both reduced eGFR and elevated albuminuria are independently associated with increased risk of death from any cause and cardiovascular death.
View studyGlobal Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
Strong evidenceHill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FDR · PLOS ONE · 2016
A systematic review and meta-analysis found a global chronic kidney disease prevalence of 11–13%, with the large majority of cases falling into disease stage 3.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
223 publications on this site
Medical review
dr Katarzyna LewandowskaCardiologist
Katarzyna works as a cardiologist at a Warsaw teaching hospital and has spent years focused on cardiovascular prevention — trying, as she puts it, to convince people to change their habits before they end up on her ward, not after. She joined VitMode after a series of conversations with Anna at a lifestyle-medicine conference, where the two discovered they shared the same frustration: an internet full of contradictory claims about cholesterol, aspirin and heart supplements, with no clear signal of what's actually backed by research. She reviews content on cardiovascular health, lipid panels and pharmacological prevention, consistently distinguishing what helps a statistical population from what makes sense for a specific person. Off duty, she road-cycles — not for performance, but because, in her words, it's hard to write credibly about prevention without practicing it yourself.
34 publications on this site
Related entries
4.7Creatinine and eGFR (Estimated Glomerular Filtration Rate)
Creatinine alone tells you surprisingly little about kidney function — only converting it into eGFR using the CKD-EPI equation reveals how much filtration capacity actually remains.
4.7Hypertension
The 'silent killer' — it runs symptom-free for years, yet it's one of the strongest, and largely modifiable, risk factors for stroke and heart attack in the world.
4.7Type 2 Diabetes
A chronic metabolic disease in which the body loses its ability to properly regulate blood glucose — and one of the few chronic diseases where a large randomized trial showed that lifestyle change alone can outperform a drug.
4.6Electrolytes: Sodium, Potassium, and Chloride
Sodium, potassium, and chloride sound like a chemistry-class topic, but their blood levels determine how your heart, muscles, and kidneys function — and even a small deviation can be an urgent warning sign.
4.7Kidney Stones
Mineral deposits forming in the urinary tract when the concentration of lithogenic substances in urine exceeds its solubility threshold — a classic RCT by Borghi showed that simply increasing fluid intake by nearly half cuts recurrence risk.
4.6Uric Acid (Blood Test)
Uric acid is the end product of purine breakdown — its blood test helps assess the risk of gout and kidney stones, but a single result on its own neither confirms nor rules out disease.
4.5Total Protein and Albumin Blood Test
Total protein and albumin are among the oldest, yet also most ambiguous, laboratory panels — the same low result can mean malnutrition, kidney disease, chronic inflammation, or simply blood dilution from IV fluids, and telling these scenarios apart takes more than a single number on a printout.
Related articles
PoradnikiChronic Kidney Disease: Symptoms and Stages — What Does Your eGFR Result Mean?
Chronic kidney disease develops silently — often over years or decades — with no symptoms at all, even as the kidneys gradually lose their ability to filter blood. By the time fatigue, swelling, or changes in urination appear, the disease is frequently already advanced. We explain how to interpret an eGFR result, how the stages differ, why diabetes and hypertension account for most cases, and when dialysis genuinely becomes necessary.
September 21, 2026
PoradnikiHigh-Protein Diets and Kidneys: Do They Harm Healthy People?
"Too much protein wrecks your kidneys" is a warning almost everyone hears the moment they start eating more meat or protein powder. A systematic review shows higher protein intake raises glomerular filtration rate (GFR) — but that means the kidney is working harder within normal range, not that it's being damaged. There's an honest catch, though: almost no study ran longer than six months, so the truly long-term question remains open.
August 23, 2026
PoradnikiHydration and Kidney Stones — How Much Does It Really Cut Recurrence Risk?
Kidney stones are one of the conditions with the highest recurrence risk in medicine — for someone who has already had one episode, another stone is more a matter of time than chance. A classic 5-year randomized trial from Parma showed that one simple, cheap, and practically safe intervention — just drinking more — meaningfully and measurably reduces that risk. It's a rare case in medicine where such strong evidence backs such simple advice.
August 26, 2026
PoradnikiKidney Stones: Symptoms and Treatment — From Renal Colic to Surgery
Kidney stones affect nearly 1 in 11 people over a lifetime, and anyone who's already had one episode faces a notably elevated risk of another. We explain how to recognize renal colic, how the different stone types differ, when it's reasonable to just wait for a stone to pass on its own, and when lithotripsy or an endoscopic procedure becomes necessary.
September 21, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.